185 related articles for article (PubMed ID: 32923159)
21. New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.
Arrieta O; Zatarain-Barrón ZL; Cardona AF
Lancet Oncol; 2020 May; 21(5):605-607. PubMed ID: 32224305
[No Abstract] [Full Text] [Related]
22. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Fernández-Teruel C; Fudio S; Lubomirov R
Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
[TBL] [Abstract][Full Text] [Related]
23. Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade.
Kroemer G; Kepp O
Oncoimmunology; 2021; 10(1):1996686. PubMed ID: 34745770
[TBL] [Abstract][Full Text] [Related]
24. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
[TBL] [Abstract][Full Text] [Related]
25. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Xie W; Forveille S; Iribarren K; Sauvat A; Senovilla L; Wang Y; Humeau J; Perez-Lanzon M; Zhou H; Martínez-Leal JF; Kroemer G; Kepp O
Oncoimmunology; 2019; 8(11):e1656502. PubMed ID: 31646106
[TBL] [Abstract][Full Text] [Related]
26. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
27. ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2023 Aug; 15(8):e17313. PubMed ID: 37491889
[TBL] [Abstract][Full Text] [Related]
28. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
30. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
31. Lurbinectedin (Zepzelca) for small-cell lung cancer.
Med Lett Drugs Ther; 2022 Nov; 64(1663):e198-e199. PubMed ID: 36384771
[No Abstract] [Full Text] [Related]
32. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
[TBL] [Abstract][Full Text] [Related]
33. Lurbinectedin-induced thrombocytopenia: the role of body surface area.
Papachristos A; Ratain MJ
Cancer Chemother Pharmacol; 2022 May; 89(5):573-575. PubMed ID: 35362793
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.
Yokoi E; Mabuchi S; Shimura K; Komura N; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Invest New Drugs; 2019 Oct; 37(5):818-827. PubMed ID: 30374654
[TBL] [Abstract][Full Text] [Related]
35. The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.
Tumini E; Herrera-Moyano E; San Martín-Alonso M; Barroso S; Galmarini CM; Aguilera A
Mol Cancer Res; 2019 Mar; 17(3):773-782. PubMed ID: 30552231
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy.
Povo-Retana A; Landauro-Vera R; Alvarez-Lucena C; Cascante M; Boscá L
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257245
[TBL] [Abstract][Full Text] [Related]
37. Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
Wahab A; Rafae A; Mushtaq K; Venkata K; Sarmad R
Am J Case Rep; 2021 Jun; 22():e932081. PubMed ID: 34125741
[TBL] [Abstract][Full Text] [Related]
38. Lurbinectedin for metastatic small-cell bladder carcinoma.
Boudin L; Patient M; Romeo E; Bladé JS; de Lesquen H
Eur J Cancer; 2021 Jul; 151():1-2. PubMed ID: 33951544
[No Abstract] [Full Text] [Related]
39. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
